Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.